Skip to main content
padlock icon - secure page this page is secure

Targets of 3-Bromopyruvate, A New, Energy Depleting, Anticancer Agent

Buy Article:

$68.00 + tax (Refund Policy)

3-bromopyruvate (3-BrPA), a pyruvate analog recently proposed as a possible anticancer drug, was investigated in relation to its capacity to inhibit energy production in fractions obtained from normal cells (rat hepatocytes) and in isolated rat thymocytes. Findings were that main targets of the drug were glyceraldehyde 3-phosphate dehydrogenase, and not hexokinase as suggested for hepatoma cells, and succinate -driven ATP synthesis. Consistently with the above findings, in the normal cells studied (thymocytes) the drug elicited an important fall in ATP levels. The significance of the present findings in concern with a possible therapeutic usefulness of the drug is discussed.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 3-Bromopyruvate; Warburg effect; glyceraldehyde-3-phosphate dehydrogenase; glycolysis; hexokinase; oxidative phosphorylation; succinate dehydrogenase; tumor therapy

Document Type: Research Article

Publication date: November 1, 2009

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more